Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration

Au, Adrian; Parikh, Vishal S.; Singh, Rishi P.; Ehlers, Justis P.; Yuan, Alex; Rachitskaya, Aleksandra; Sears, Jonathan E.; Srivastava, Sunil K.; Kaiser, Peter K.; Schachat, Andrew P.; Martín, Daniel; Modi, Yasha S.

doi:10.1136/bjophthalmol-2016-309434

Cited by 23 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…presented that the mean decrease of central macular thickness was 78.3 ± 113.9 μm in the regular treated group and 75.3 ± 126.1 μm in irregular treated group. These results were comparable to our results (51.9 ± 58.2 μm) 12, 14, 15…”

Section: Discussionsupporting

confidence: 93%

The results of aflibercept therapy as a first line treatment of age-related macular degeneration

Unsal¹,

Çubuk²

2019

Journal of Current Ophthalmology

View full text Add to dashboard Cite

Purpose To report the results of aflibercept treatment in treatment-naive neovascular age-related macular degeneration (AMD) patients and suggest a suitable treatment algorithm for routine clinical practice. Method The medical charts of patients treated with intravitreal aflibercept for neovascular AMD were reviewed retrospectively. Best corrected visual acuity, slit-lamp examination, dilated fundus examination, applanation tonometry, and a total number of aflibercept injections were recorded. Aflibercept therapy was applied in an as-needed algorithm after three monthly loading dose. Additionally, optic coherence tomography data, including presence or absence of macular fluid and central macular thickness were recorded. Results Thirty-eight eyes of 36 patients were included in this study. The mean number of aflibercept injections was 4.86 ± 2.76 (3–18). Mean follow-up time was 12.1 ± 5.7 months (6–26). Thirty-seven eyes (97.3%) achieved maintenance of vision. The mean best corrected visual acuity (logMAR) increased from 0.98 ± 0.56 (0.2–2.4) to 0.57 ± 0.31 (0.1–1.3), ( P = 0.001). Mean visual acuity gain was 15.86 ± 12.18 letters at the end of the study. The mean central macular thickness decreased from 327.9 ± 56.5 μm (219–474 μm) to 277.0 ± 53.0 μm (197–405 μm), ( P = 0.016). Conclusions Aflibercept therapy appears to be a safe and effective treatment for neovascular AMD. Injections applied in an as-needed algorithm after three monthly loading doses were successful to maintain and improve visual acuity.

show abstract

Section: Discussionsupporting

confidence: 93%

The results of aflibercept therapy as a first line treatment of age-related macular degeneration

Unsal¹,

Çubuk²

2019

Journal of Current Ophthalmology

View full text Add to dashboard Cite

show abstract

“…En-phase OCTA shows the CNV, which in this case demonstrates signs of maturity (prominent trunk vessels, pruning). This case was considered a ' 'silent CNV' ' due to the absence of exudative signs throughout follow-up aflibercept [63]. At 1 year, there was no statistically significant VA change in either group.…”

Section: Fibrovascular/haemorrhagic Pedsmentioning

confidence: 99%

Retinal Pigment Epithelial Detachment in Age-Related Macular Degeneration

Karampelas

Malamos²,

Petrou

et al. 2020

Ophthalmol Ther

View full text Add to dashboard Cite

Retinal pigment epithelial detachment is defined as a separation of the retinal pigment epithelium from the inner collagenous layer of Bruch's membrane. It is a common manifestation in both dry and wet types of age-related macular degeneration. This review aims to provide a comprehensive guide to the pathophysiology, clinical and imaging characteristics, natural course and treatment of the various types of pigment epithelial detachments in order to assist in diagnosis and management of this important feature of age-related macular degeneration.

show abstract

“…Nevertheless, SD-OCT is a key element in detecting recurrences, and treatment decisions are frequently based solely on this noninvasive imaging method [ 7 – 9 ]. Classically, recurrences of CNV are defined on SD-OCT by a myriad of signs, ranging from subretinal or intraretinal fluid, subretinal hyperreflective material, or changes in the pigment epithelial detachment's height [ 7 – 11 ].…”

Section: Introductionmentioning

confidence: 99%

Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen

Mière

Amoroso

Butori

et al. 2018

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose To compare the qualitative and quantitative choroidal neovascularization (CNV) changes after antivascular endothelial growth factor (anti-VEGF) therapy in treatment-naïve and treated eyes with age-related macular degeneration (AMD) using optical coherence tomography angiography (OCTA). Methods Consecutive patients with neovascular AMD underwent multimodal imaging, including OCTA (AngioPlex, CIRRUS HD-OCT model 5000; Carl Zeiss Meditec, Inc., Dublin, OH) at baseline and at three monthly follow-up visits. Treatment-naive AMD patients undergoing anti-VEGF loading phase were included in group A, while treated patients were included in group B. Qualitative and quantitative OCTA analyses were performed on outer retina to choriocapillaris (ORCC) slab. CNV size was measured using a free image analysis software (ImageJ, open-source imaging processing software, 2.0.0). Results Twenty-five eyes of 25 patients were enrolled in our study (mean age 78.32 ± 6.8 years): 13 treatment-naïve eyes in group A and 12 treated eyes in group B. While qualitative analysis revealed no significant differences from baseline to follow-up in the two groups, quantitative analysis showed in group A a significant decrease in lesion area (P = 0.023); in group B, no significant change in the lesion area was observed during anti-VEGF therapy (P = 0.93). Conclusion Treatment-naïve and treated eyes with CNV secondary to neovascular AMD respond differently to anti-VEGF therapy. This should be taken into account when using OCTA for CNV follow-up or planning therapeutic strategies.

show abstract

Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration

Cited by 23 publications

References 15 publications

The results of aflibercept therapy as a first line treatment of age-related macular degeneration

The results of aflibercept therapy as a first line treatment of age-related macular degeneration

Retinal Pigment Epithelial Detachment in Age-Related Macular Degeneration

Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen

Contact Info

Product

Resources

About